Kornimate/medical-research-clean huggingface dataset:
effectiveness study of atrial fibrillation

Conditions: Atrial Fibrillation

Summary: this is an international observational multicentre study to be conducted in germany, spain, italy and usa. the main objective of the study is to evaluate the relative effectiveness of dronedarone in real world clinical practice versus other anti-arrhythmic agents of interest. the design of the study is a historic-prospective cohort with dynamic exposure and stratified competitive recruitment with balanced comparison groups of dronedarone versus alternative antiarrhythmic drugs of interest.


Eligibility criteria:
inclusion criteria: * patient 18 years old or above * patient with paroxysmal or persistent atrial fibrillation * patient using an aai (antiarrhythmic drug of interest) or dronedarone (index drug) * patient's treatment changed from one aai to another aai or dronedarone or from no antiarrhythmic therapy to the start of aai or dronedarone therapy during previous 6 months before the date of recruitment * patient with at least 6 months of medical and treatment information prior to the start of the index drug * patient able to answer the telephone interview in a language of the participating country: english, german, italian or spanish (with or without proxy). exclusion criteria: * patient with heart failure (nyha class iv) * patient with permanent atrial fibrillation * patient with psychiatric conditions preventing the participation to the study according to the physician

Keywords: atrial fibrillation dronedarone cohort effectiveness
iron substitution after upper gastro-intestinal bleeding

Conditions: Gastrointestinal Hemorrhage; Anemia

Summary: the trial is a double-blind randomized trial designed to examine whether compliant iron therapy (intravenous or oral) for 3 months after discharge increases hemoglobin levels more and faster than no treatment - in patients with acute bleeding from upper gastrointestinal tract. the trial will include 126 patients at aarhus university hospital. in addition to efficacy assessment quality of life assessment and health economic calculations between the treatments will be compared.


Eligibility criteria:
inclusion criteria: * acute upper gastrointestinal bleeding * anemia exclusion criteria: * liver disease * terminal cancer * kidney disease * variceal bleeding * pregnancy

Keywords: iron treatment upper gastrointestinal bleeding
combined interventions for treating depression and chronic back pain

Conditions: Back Pain; Depression

Summary: this study will determine the effectiveness of an intervention consisting of combined strategies in reducing the symptoms of both depression and chronic back pain.

the relationship between depression and back pain is complex. depression is the most common mental condition associated with chronic back pain. despite this relationship, many patients with depression and back pain seek treatment only for one of the two conditions, which can worsen the untreated condition. an intervention that reduces the symptoms of both depression and back pain is needed. this study will determine the effectiveness of an integrated intervention in reducing both back pain and depression symptoms. participants will be randomly assigned to receive either an integrated intervention or standard of care for 6 months. participants in the integrated intervention group will receive cognitive behavioral therapy for back pain and antidepressants and/or problem solving therapy for depression. study visits will initially occur once a week and then taper to once every 2 weeks for the 6-month duration; the time of tapering will depend on participant response to treatment and will be at the investigator's discretion. depression and back pain symptoms will be assessed in all participants at study entry, at the end of treatment, and 6 months after the end of treatment. the study entry and study completion assessments will occur during study visits. the last assessment will be a telephone interview.

Eligibility criteria:
inclusion criteria: * roland back pain score of 7 or greater * diagnosis of major depression * plan to stay enrolled in group health cooperative for the duration of the study and 1 year after the study exclusion criteria: * prior surgery * cauda equina syndrome (compression and paralysis of nerve roots) * schizophrenia or bipolar disorder treatment within 2 years prior to study entry * current or prior psychiatric or psychological care for back pain or depression * at high risk for suicide

Keywords: cognitive behavioral therapy problem solving therapy cbt
an open-label study of intra-articular amb-05x injections in subjects with tenosynovial giant cell tumor of the knee

Conditions: Tenosynovial Giant Cell Tumor; Pigmented Villonodular Synovitis (PVNS)

Summary: amb-051-01 is a multicenter study with an adaptive design that will enroll subjects with tenosynovial giant cell tumor (tgct) of the knee for 12 weeks of multiple-dose, open-label treatment with intra-articular amb-05x.

amb-05x drug substance is a human monoclonal antibody against the colony-stimulating factor 1 receptor (csf1r). study

Eligibility criteria:
inclusion criteria: 1. subject ≥ 18 years 2. a confirmed diagnosis of tenosynovial giant cell tumor (tgct) of the knee joint 3. measurable disease based on recist v1.1 4. stable prescription of analgesic regimen 5. negative urine drug screen (uds) at screening and baseline 6. women of childbearing potential must have a negative pregnancy test 7. agrees to follow contraception guidelines 8. adequate hematologic, hepatic, and renal function, at screening 9. willing and able to complete self-assessment instruments throughout the study exclusion criteria: 1. prior investigational drug use within 4 weeks or 5 half-lives of baseline 2. previous use of therapeutics targeting csf1 or csf1r or oral tyrosine kinase inhibitors 3. history of extensive knee surgery 4. active cancer (either currently or within 1 year before baseline) that requires therapy (e.g., surgery, chemotherapy, or radiation therapy) 5. metastatic tgct 6. hepatitis c virus (hcv) or hepatitis b virus (hbv) or human immunodeficiency virus (hiv) 7. known active tuberculosis 8. significant concomitant arthropathy in the affected joint, serious illness, uncontrolled infection, or a medical or psychiatric history 9. women who are breastfeeding 10. a screening fridericia-corrected qt interval (qtcf) ≥ 450 ms (men) or ≥ 470 ms (women) 11. mri contraindications (e.g., pacemaker, loose metallic implants) 12. history of hypersensitivity to any ingredient of the study drug 13. history of drug or alcohol abuse within 3 months before the first dose of study drug 14. any other severe acute or chronic medical or psychiatric condition or clinically significant laboratory abnormality that may increase the risk associated with study participation/treatment or interfere with interpretation of study results and, in the investigator's opinion, make the subject inappropriate for this study 15. subjects who, in the investigator's opinion, should not participate in the study for any reason, including if there is a question about their ability to comply with study requirements

Keywords: tenosynovial giant cell tumor (tgct) pigmented villonodular synovitis (pvns) tgct pvns
why still in hospital after hip fracture surgery?

Conditions: Hip Fractures

Summary: at our institution, hip fracture patients are admitted and treated according to a fast track patient pathway. the aim of this study is to identify areas of this patient pathway that can be improved. to achieve this, the study will investigate the underlying reasons for the continued need for hospitalization on the consecutive days after hip fracture surgery.

the study will be conducted at the orthopedic department, akershus university hospital, as a prospective observational study and will include approximately 200 consecutive hip fracture patients. the patients will be evaluated once daily for the fulfillment of predefined discharge criteria. if the discharge criteria are not met or if the criteria are met but the patient is not discharged in spite of this the underlying reason(s) are recorded.

Eligibility criteria:
inclusion criteria: * operated at the orthopedic department, akershus university hospital, for a hip fracture exclusion criteria: * lack of written informed consent

Keywords: fast track
anxiety and depression in relatives of critically ill patients: spouses versus other close relatives

Conditions: Stress Disorders, Post-Traumatic; Anxiety; Depression

Summary: the main objective of this study is to compare the rate of reported anxiety / depression (hads \>= 8) among spouses and other family members in icu patients.

the secondary objectives of this study are: * to assess symptoms of anxiety (hads ≥ 8) and depression (hads ≥ 8) among relatives of icu patients three months after discharge * to assess what relatives felt vis-à-vis the information process * describe the number and duration of interviews with participants * to compare variables between the groups "spouses" and "other relatives". * satisfaction * number and duration of interviews * hads questionnaire * the scale edmunton * an internal questionnaire * ies-r score * level of mental well-being: wemwbs * to describe the completeness of the study * to test the hypothesis that the development of symptoms related to physical manifestations of anxiety and depression predicts the development of post-traumatic stress at 3 months. * to assess the impact of the various forms of stress during hospitalization.

Eligibility criteria:
inclusion criteria: * the relative must have given his/her informed and signed consent * the relative must be insured or beneficiary of a health insurance plan * the relative must be available for 3 months of follow-up exclusion criteria: * the relative is under judicial protection, under tutorship or curatorship * the relative refuses to sign the consent * it is impossible to correctly inform the relative

Keywords: intensive care unit
newborn genomics programme

Conditions: Genetic Disease; Newborn Morbidity

Summary: genomic methods can significantly contribute to all facets of precision medicine, from diagnosis to prevention, therapeutic intervention, and management of acute and chronic illnesses. dna based methods are already having a considerable impact across healthcare in fields that include: public health, infectious disease monitoring, acute and chronic disease, pharmacogenomics, prenatal testing and diagnosis, and therapeutic development. in this proposal, investigators are focusing on the application of genomic methods in precision medicine - specifically on rapid whole-genome sequencing of parents and children (i.e. a trio) for the identification of diseases that have genetic components. goals primary goal: is to provide safe rapid whole genome sequencing to neonatal intensive care unit/pediatric intensive care unit patients. secondary goals: 1) although several groups globally are implementing rapid sequencing of rare disease, these are predominantly in the research space, with many unanswered questions regarding the best way to implement them into a national healthcare system. each country and their healthcare systems are unique, and valuable knowledge will be gained by implementing this process within a new zealand context. as part of this the study will measure the impact on the individuals and families. 2) to expand the research team's understanding of non-coding disease-causing variants and methylation changes that contribute to severe disease in early life. primary aims 1. to incorporate long-read rna sequencing data into the diagnostic rapid whole genome sequencing pipeline to provide a direct measure of the functional outcome of the variants of clinical concern. 2. to measure the clinical utility of analysing non-coding variants in the diagnosis of critically ill children who do not have pathogenic, likely pathogenic, or variants of unknown significance for mendelian disorders. 3. to identify, in a real-world setting within the new zealand health-care system, the clinical and economic effects of deploying rapid whole genome sequencing-informed rapid precision medicine for critically ill children.


Eligibility criteria:
inclusion criteria: * acutely ill inpatient * admitted to nicu or picu between april 2023 - march 2026 * within 1 week of hospitalization or within 1 week of development of abnormal response to standard therapy for an underlying condition * suspected genetic condition, without a clear non-genetic aetiology exclusion criteria: * patients whose clinical course is entirely explained by * isolated prematurity * isolated unconjugated hyperbilirubinemia * infection or sepsis with expected response to therapy * a previously confirmed genetic diagnosis that explains the clinical condition - * isolated transient neonatal tachypnoea * meconium aspiration syndrome * trauma * inability to source blood and buccal samples for dna extraction from at least the mother and child
topical tranexamic acid plus bilateral uterine artery ligation during cesarean delivery

Conditions: Cesarean Section Complications

Summary: placenta previa (pp) is an obstetric condition that is closely linked with massive obstetric hemorrhage with a varied incidence about once in every 200 live births. it is considered one of the causes of the increased need for blood transfusion and cesarean hysterectomy. pph due to pp typically starts during cesarean section (cs) in the placental bed, at the lower uterine segment mostly after placental separation. proceeding for cesarean hysterectomy can be the only effective line of management in spite of the associated high morbidity rate. various conservative measures have been developed to avoid hysterectomy and preserve fertility in patients with pp. bilateral uterine artery ligation (bual) is one of the reported surgical procedures carried out in these cases as it is easy and quick. it can be used alone or with adjunctive measures with a fair success rate. the aim is to reduce the blood supply to the uterus and to prevent postpartum hemorrhage. tranexamic acid is a lysine analog which acts as an antifibrinolytic via competitive inhibition of the binding of plasmin and plasminogen to fibrin. the rationale for its use in the reduction of blood loss depending on the implication of the coagulation and fibrinolysis processes implicated in the control of pph. however, concerns about possible thromboembolic events with parenteral administration of ta have stimulated increasing interest in its topical use.

study inclusion criteria will be women undergoing elective cesarean delivery for complete placenta previa which not respond uterotonic and simple hemostatic maneuvers like placental bed hemostatic sutures eligible participants were allocated to one of two groups. group (i): patients managed by bilateral uterine artery ligation (bual) after delivery of the fetus which not respond uterotonic and simple hemostatic maneuvers like placental bed hemostatic sutures. group (ii): patients received 1 gm ta (2 ampoules of capron® 500 mg /5 ml; cairo, egypt) topically applied to the placental bed plus bua when not respond to uterotonic and simple hemostatic maneuvers like placental bed hemostatic sutures.

Eligibility criteria:
inclusion criteria: * women undergoing elective cesarean delivery for complete placenta previa which not respond uterotonic and simple hemostatic maneuvers like placental bed hemostatic sutures exclusion criteria: * patients with the high possibility of morbid adherent placenta * those presented with severe antepartum hemorrhage * patients with cardiac, hepatic, renal, or thromboembolic disease; * hypersensitivity or contraindications of use of tranexamic acid * patient refuses to consent

Keywords: placenta previa tranexamic acid uterine artery ligation
omega 7 oil and inflammatory biomarker study

Conditions: Musculoskeletal Pain

Summary: the purpose of the study is to determine whether the palmitoleic acid supplementation can reduce the serum inflammatory biomarkers and low quality of life scores due to musculoskeletal discomfort. the study design is a 2-arm placebo-controlled double blind crossover trial. the randomized sequence of a single crossover is divided into 1:1 and each supplementation is three weeks with no washout in between.

the purpose of the study is to investigate whether or not the supplementation of a particular omega-7 fatty acid decreases the serum biomarkers of inflammation, i.e. highly sensitive c-reactive protein, tnf-alpha and il-6 of participants who have been experiencing decreased quality of life (qol) and having elevated these serum markers. the study is placebo-controlled and conducted in a double blinded manner. participants will be crossed over on supplements (active and placebo) in a random sequence. the total length of a trial is six weeks in which the participants will be asked to maintain stable diet. the baseline blood draw, physical exam, range of motion, qol and dietary assessment and taking vitals are performed. after the blood test results and/or qol assessment confirm the eligibility, three weeks supply of the investigational supplement will be mailed or picked up in person. the supplementation is one gel-capusule a day for three weeks. at the end of three weeks, another blood draw, physical exam, range of motion, and qol assessment are conducted; then the other investigational supplement will be provided. the assessment of the second supplement will occur after another three-week mark. if no adverse reaction is observed and there is no concerns, the participant will be exited from the study. the goal of enrollment is 50 participants who are between 18 to 99 years old with decreased quality of life and potentially elevated serum markers of inflammation. volunteers will be randomized by a block of four so at any given moment, one group does not exceed more than three participants. the study takes place at kenmore campus.

Eligibility criteria:
inclusion criteria: (any of the below) * baseline crp 1.0 mg/l or higher * \> 3 months (chronic) musculoskeletal pain/discomfort, which the participant is able to monitor during the course of trial (6 weeks) exclusion criteria: * taking narcotic or opioid pain medication * unable to monitor nsaid or otc pain medication quantity * unable to visit kenmore washington clinical research center for three times * objection from his/her primary care doctor * employee or family member of barlines organics
a study of ciclesonide nasal spray in patients 18 years and older with seasonal allergic rhinitis (by9010/m1-413)

Conditions: Rhinitis, Allergic, Seasonal; Hay Fever

Summary: the purpose of this study is to investigate the safety and effectiveness of ciclesonide nasal spray as compared with placebo (inactive substance) nasal spray in relieving symptoms of seasonal allergic rhinitis caused by pollen. ciclesonide will be administered once during the exposure to ragweed pollen in a controlled environment. the study duration consists of a baseline period (up to 5 days) and a treatment period (1 day). the study will provide further data on safety and tolerability of ciclesonide.


Eligibility criteria:
main inclusion criteria: * written informed consent * general good health * history of sar to short ragweed pollen for 2 years immediately preceding the study * demonstrated sensitivity to short ragweed known to induce sar through a standard skin prick test main exclusion criteria: * clinically significant physical finding of nasal anatomical deformities causing greater than 50% obstruction, including but not limited to nasal polyps, septal defects, respiratory tract malformations, nasal trauma or surgery * known hypersensitivity to any corticosteroid * history of a respiratory infection or disorder including but not limited to bronchitis, pneumonia, chronic sinusitis, influenza or sars (severe acute respiratory syndrome) within 14 days preceding the screening visit * history of alcohol or drug abuse within 2 years preceding the screening visit * active asthma requiring treatment of inhaled or systemic corticosteroids and/or routine use of beta-agonists or any controller drugs * use of antibiotic therapy for acute conditions within 14 days preceding the screening visit * exposure to systemic corticosteroids for any indication, chronic or intermittent within 60 days preceding the screening visit

Keywords: seasonal allergic rhinitis ciclesonide hay fever sar
effects of progressive relaxation exercises

Conditions: Nursing Caries; Progression; Sleep

Summary: when the literature is examined, it is observed that the effects of progressive relaxation exercises on pain, anxiety and sleep quality have been frequently investigated in different populations. studies conducted with nursing students focus on dysmonorrhea and clinical anxiety and stress . a limited number of studies have focused on the quality of life of students . there is no study examining the effects of progressive relaxation exercises on sleep quality, psychological endurance and quality of life together. therefore, the aim of our study is to examine the effects of progressive relaxation exercises applied to nursing students on sleep quality, psychological endurance and quality of life. it is thought that our study results will contribute to the literature in terms of their originality.

this research is a randomized controlled trial planned to examine the effects of progressive relaxation exercises on sleep quality, psychological resilience and quality of life in nursing students.

Eligibility criteria:
inclusion criteria: * being a student in the department of nursing * being willing to participate in the study * not having a chronic disease that may prevent exercise (copd, heart failure, etc.) * not having a hearing problem * not having a psychiatric diagnosis (major depression, anxiety disorders, etc.) and not using medication for anxiety or depression * having a computer and technological devices at home * being able to use a mobile phone (ios-android) * having internet access * being able to speak turkish * not having used techniques such as meditation, hypnosis, yoga for the last 6 months before the study * not having a neurological, systemic, or psychiatric disease. exclusion criteria: * • nursing students who do not volunteer to participate in the study, * those who have any health problems during the application process, * those who cannot continue the study for any reason, * those who want to withdraw from the study with their own consent
comparison of viescope vs. macintosh laryngoscope for intubation in level cpersonal protective equipment conditions

Conditions: Tracheal Intubation; Infection; Projection

Summary: the current covid-19 pandemic, this is especially since the transmission of sars-cov-2 is thought to occur mainly through respiratory droplets generated by coughing and sneezing, by direct contact with contaminated surfaces and because in a large number of patients covid-19 disease may be asymptomatic. as recommended by the cdc for aerosol-generating procedures (agp), medical personnel should be equipped with full personal protective equipment (ppe) for agp. therefore, it is reasonable to search for the most effective methods of intubation in those conditions.


Eligibility criteria:
inclusion criteria: * paramedic * consent voluntary participation in the study * none experience in vie scope * none experience in intubation with personal protective equipment exclusion criteria: * refusal to participate in the study

Keywords: sars-cov-2 covid-19 tracheal intubation laryngoscope personal protective equipment
locoregional blocks for breast cancer surgeries

Conditions: Analgesia

Summary: breast surgeries are common operative procedures that require appropriate postoperative analgesia.

numerous pain relief techniques, including several new regional anesthesia techniques, are available for control of acute pain after breast surgery.

Eligibility criteria:
inclusion criteria: * female cancer breast patient * age from 18- 65 exclusion criteria: * coagulation defect * patient refusal * abnormal kidney and or liver function tests